OC.16.4: SEMAGLUTIDE FOR TYPE 2 DIABETES CONTROL IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A TWO-WAY EFFECT?

MLA

Petralli, G., et al. “Oc.16.4: Semaglutide for Type 2 Diabetes Control in Metabolic Dysfunction-Associated Steatotic Liver Disease (Masld): A Two-Way Effect?” Digestive & Liver Disease, vol. 56, Apr. 2024, p. S204. EBSCOhost, https://doi.org/10.1016/S1590-8658(24)00527-9.

APA

Petralli, G., Salvati, A., Cappelli, S., Surace, L., Ricco, G., Colombatto, P., Solini, A., & Brunetto, M. R. (2024). Oc.16.4: Semaglutide for Type 2 Diabetes Control in Metabolic Dysfunction-Associated Steatotic Liver Disease (Masld): A Two-Way Effect? Digestive & Liver Disease, 56, S204. https://doi.org/10.1016/S1590-8658(24)00527-9

Chicago

Petralli, G., A. Salvati, S. Cappelli, L. Surace, G. Ricco, P. Colombatto, A. Solini, and M.R. Brunetto. 2024. “Oc.16.4: Semaglutide for Type 2 Diabetes Control in Metabolic Dysfunction-Associated Steatotic Liver Disease (Masld): A Two-Way Effect?” Digestive & Liver Disease 56 (April): S204. doi:10.1016/S1590-8658(24)00527-9.